Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Miroslav Ravic"'
Autor:
J. Alfred Witjes, Henk Vergunst, Theo M. de Reijke, Rianne J.M. Lammers, Harm C. Arentsen, Erik B. Cornel, J. Falke, Miroslav Ravic, Raffaella Pozzi
Publikováno v:
Journal of Urology, 189, 2077-82
Journal of Urology, 189, 6, pp. 2077-82
Journal of urology, 189(6), 2077-2082. Elsevier Inc.
Journal of Urology, 189, 6, pp. 2077-82
Journal of urology, 189(6), 2077-2082. Elsevier Inc.
Item does not contain fulltext PURPOSE: Imiquimod, a toll like receptor 7 (TLR-7) agonist, is effective as a topical treatment for skin malignancies. TMX-101 is a liquid formulation of imiquimod. In this study we establish a safety profile of TMX-101
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0039e7e177e66942f261c5b888462ab3
https://doi.org/10.1016/j.juro.2012.11.150
https://doi.org/10.1016/j.juro.2012.11.150
Autor:
Peter Bytzer, Anna Morocutti, Peter Kennerly, Miroslav Ravic, Neil Miller, null ON BEHALF OF THE ROSE TRIAL INVESTI
Publikováno v:
Scandinavian Journal of Gastroenterology. 41:1132-1140
Gastro-oesophageal reflux disease (GORD) symptoms have a significant impact on patients' well-being. Onset of symptom relief is therefore an important consideration in GORD treatment. The primary objective was to compare the efficacy of rabeprazole (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7bee4d114d387869b5afe3d0da94c65
https://doi.org/10.1080/00365520600615781
https://doi.org/10.1080/00365520600615781
Autor:
Rianne J.M. Lammers, J. Alfred Witjes, Andreas Eisenhardt, Irene Rustighini, Antoine G. van der Heijden, Henk Vergunst, Miroslav Ravic, J. Falke, Raffaella Pozzi, Tom J.H. Arends
Publikováno v:
Clinical Genitourinary Cancer, 13, 3, pp. 204-209.e2
Clinical Genitourinary Cancer, 13, 204-209.e2
Clinical Genitourinary Cancer, 13, 204-209.e2
Item does not contain fulltext INTRODUCTION/BACKGROUND: Non-muscle-invasive bladder cancer (NMIBC) has a strong tendency to recur despite adjuvant instillations. TMX-101 is a new liquid form of imiquimod for intravesical instillation and has activity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3703e11dbeafc623389065a6a3400ab3
https://doi.org/10.1016/j.clgc.2014.12.010
https://doi.org/10.1016/j.clgc.2014.12.010
Autor:
Mark J. McKeage, Bruce C. Baguley, Michael B. Jameson, Mark Jeffery, Miroslav Ravic, Peter C.C. Fong, Phil Kestell
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 12(6)
This phase I safety study aimed to identify the optimal dose of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) for combination studies. Using a crossover design, 15 patients with refractory tumors were allocated randomly t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f9058e4912d655148f7a7e1ef5b0156
https://pubmed.ncbi.nlm.nih.gov/16551862
https://pubmed.ncbi.nlm.nih.gov/16551862
Autor:
Christian, Dittrich, Herlinde, Dumez, Hilary, Calvert, Axel, Hanauske, Marije, Faber, Jantien, Wanders, Murray, Yule, Miroslav, Ravic, Pierre, Fumoleau
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(14)
E7070 is a sulfonamide that induces arrest at the G(1)-S boundary with subsequent dose and exposure-dependent apoptosis. The objectives of this study were (a) to determine the maximum-tolerated dose (MTD) and recommended safe dose (RD) of E7070 for a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8c6a1a167bada520e9d085e346b84f89
https://pubmed.ncbi.nlm.nih.gov/14613999
https://pubmed.ncbi.nlm.nih.gov/14613999
Autor:
Achim Rothe, Horst-Dieter Hummel, Stephanie Sasse, Bastian von Tresckow, Max S. Topp, Dennis A. Eichenauer, Jens-Peter Marschner, Andreas Engert, Miroslav Ravic
Publikováno v:
Blood. 124:1753-1753
Introduction: AFM13 is a bispecific, tetravalent TandAb antibody that targets CD16A and CD30. Preclinical data demonstrated that AFM13 specifically harnessed NK cells to exert potent cytotoxic effects on tumor cells expressing CD30. Furthermore, AFM1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2902fba22ce9291c5cd5ac5d1848e74
https://doi.org/10.1182/blood.v124.21.1753.1753
https://doi.org/10.1182/blood.v124.21.1753.1753
Autor:
Miroslav Ravic, Andreas Engert, Horst Hummel, Max S. Topp, Anas Younes, Achim Rothe, Bastian von Tresckow, Katrin S. Reiners, Elke Pogge von Strandmann, Joerg Kessler, Jens-Peter Marschner
Publikováno v:
Cancer Research. 74:CT341-CT341
Introduction: Standard treatment of HL results in high cure rates. However, 30-40% of the patients relapse and 2nd line therapies induce durable remission in only 50% of the patients. AFM13 is a novel, tetravalent bi-specific antibody belonging to Af
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5cfebf86bb5eebdcb054f08a15236a2a
https://doi.org/10.1158/1538-7445.am2014-ct341
https://doi.org/10.1158/1538-7445.am2014-ct341
Autor:
Bastian von Tresckow, Achim Rothe, Horst-Dieter Hummel, Max S. Topp, Andreas Engert, Dennis A. Eichenauer, Miroslav Ravic, Jens-Peter Marschner
Publikováno v:
Journal of Clinical Oncology. 32:3025-3025
3025^ Background: AFM13 is a bispecific anti-CD30, anti-CD16A antibody construct which recruits NK cells for targeted lysis of CD30+ tumor cells. HL cells are characterized by CD30 positivity and r...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::884002bca93bc4ffecd3c90ed7102909
https://doi.org/10.1200/jco.2014.32.15_suppl.3025
https://doi.org/10.1200/jco.2014.32.15_suppl.3025
Autor:
Eugene Zhukovsky, Achim Rothe, Bastian von Tresckow, Max Topp, Anas Younes, Dennis A. Eichenauer, Horst Hummel, Katrin S. Reiners, Markus Dietlein, Joerg Kessler, Miroslav Ravic, Christian Hucke, Elke Poggevon Strandmann, Andreas Engert
Publikováno v:
Blood. 122:5116-5116
Background AFM13 is a bispecific TandAb antibody for the treatment of Hodgkin lymphoma (HL) and other CD30+ malignancies. AFM13 specifically targets both CD30, which is the antigen identifying HL tumor cells, and CD16A, for the recruitment of NK cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f05fc7c89ecfd2ca8d288f2f89a4e9fb
https://doi.org/10.1182/blood.v122.21.5116.5116
https://doi.org/10.1182/blood.v122.21.5116.5116
Autor:
Miroslav Ravic, Stefan Knackmuss, Erich Rajkovic, Eugene Zhukovsky, Anas Younes, Joerg Kessler, Horst Hummel, Max S. Topp, Christian Hucke, Markus Dietlein, Elke Pogge von Strandmann, Katrin S. Reiners, Uwe Reusch, Achim Rothe, Dennis A. Eichenauer, Andreas Engert
Publikováno v:
Cancer Research. 73:4572-4572
AFM13 represents a new class of bispecific antibodies, based on the RECRUIT-TandAb platform, which enables the generation of therapeutics with improved efficacy, convenient administration regimens, and excellent safety profiles. AFM13 was developed f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a44b8e414839472de7f8a5c615d990c
https://doi.org/10.1158/1538-7445.am2013-4572
https://doi.org/10.1158/1538-7445.am2013-4572